EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

JCMM Annual Review on Advances in Biotechnology for the Treatment of Haematological Malignancies: A Review of the Latest In‐Patient Developments 2024–2025

Akbar M Shahid iD, William Vainchenker, Stefan N Constantinescu

Journal of Cellular and Molecular Medicine · 2025-07 · 29 (13)

DOI: 10.1111/jcmm.70700 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 06.07.2025. Verfasst von Akbar M Shahid und 2 weiteren Autor:innen. Beteiligte Einrichtung: Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Biotechnology. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advances in biotechnology are set to revolutionise the treatment of haematological malignancies. Current treatments have limited efficacy due to their high toxicity and poor long‐term outcomes, particularly in acute myeloid leukaemia (AML). In 2024–2025, emerging targeted therapies promise improved results with reduced adverse effects. This review is the first of an annual series exploring the latest in‐patient developments in several key areas, focusing on mechanisms. We present advances in the use and action of several therapies including epigenetic modulators, protein degraders, apoptotic inducers, gene editing, and immunotherapy. We discuss the individual molecular mechanisms and clinical findings of these developments, emphasising their potential to improve survival and offer renewed hope for individuals with blood cancer. Importantly, such novel approaches with testing in patients should lead to further intensive efforts both at basic and translational research levels aiming at effective targeted and immunotherapy in blood cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematologic NeoplasmsBiotechnologyHumansImmunotherapyGene EditingMolecular Targeted Therapy

Stichwörter der Autor:innen

Bcl‐2 inhibitorsantibody‐drug conjugatebiotechnologybispecific antibodiescancer vaccinesepigeneticsgene therapyhaematological malignanciesmonoclonal antibodiesprotein degraders

Autor:innen und Institutionen

  • Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK.
  • INSERM UMR1287, Villejuif, France.
  • Université Paris-Saclay, Villejuif, France.
  • Gustave Roussy, Villejuif, France.
  • Ludwig Institute for Cancer Research, Brussels, Belgium.
  • Université Catholique de Louvain and de Duve Institute, Brussels, Belgium.

ORCID-Profile: Akbar M Shahid

Zitieren

APA

Shahid, A. M., Vainchenker, W., & Constantinescu, S. N. (2025). JCMM Annual Review on Advances in Biotechnology for the Treatment of Haematological Malignancies: A Review of the Latest In‐Patient Developments 2024–2025. Journal of Cellular and Molecular Medicine, 29(13). https://doi.org/10.1111/jcmm.70700

Vancouver

Shahid AM, Vainchenker W, Constantinescu SN. JCMM Annual Review on Advances in Biotechnology for the Treatment of Haematological Malignancies: A Review of the Latest In‐Patient Developments 2024–2025. Journal of Cellular and Molecular Medicine. 2025;29(13). doi:10.1111/jcmm.70700

BibTeX
@article{Shahid2025,
  author = {Shahid, Akbar M and Vainchenker, William and Constantinescu, Stefan N},
  title = {JCMM Annual Review on Advances in Biotechnology for the Treatment of Haematological Malignancies: A Review of the Latest In‐Patient Developments 2024–2025},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2025},
  volume = {29},
  number = {13},
  doi = {10.1111/jcmm.70700}
}
Kostenlos starten →